Amy Dover, LMFT in Enterprise, AL - Marriage & Family Therapist

Amy Dover, LMFT is a Marriage & Family Therapist based in Enterprise, Alabama. Amy Dover is licensed to practice in Alabama (license number 410) and her current practice location is 526 Boll Weevil Cir, Office B, Enterprise, Alabama. She can be reached at her office (for appointments etc.) via phone at (757) 515-8636.

NPI number for Amy Dover is 1851799860 and her current mailing address is Po Box 311364, Enterprise, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1851799860.

Contact Information

	Amy Dover, LMFT
	526 Boll Weevil Cir, Office B, Enterprise, AL 36330-4012
	(757) 515-8636
	Not Available

Healthcare Provider's Profile

Full Name	Amy Dover
Gender	Female
Speciality	Marriage & Family Therapist
Location	526 Boll Weevil Cir, Enterprise, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1851799860
Provider Enumeration Date: 12/08/2014
Last Update Date: 12/08/2014

Medical Identifiers

Medical identifiers for Amy Dover such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1851799860	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	410 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Amy Dover is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Amy Dover, LMFT Po Box 311364, Enterprise, AL 36331-1364 Ph: (757) 515-8636	Amy Dover, LMFT 526 Boll Weevil Cir, Office B, Enterprise, AL 36330-4012 Ph: (757) 515-8636

News Archive

Scientists develop unique cells to repair patient's defective and diseased bladder

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

Handwritten drug prescriptions contribute heavily to trio of major errors

In a small study of opioid prescriptions filled at a Johns Hopkins Medicine outpatient pharmacy, researchers found that handwritten orders for the drugs contribute heavily to a trio of prescribing and processing errors in contrast to those created electronically.

Targacept initiates TC-6987 Phase 2 study in patients with asthma, Type 2 diabetes

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.

Neurotechnology announces availability of VeriLook Surveillance 2.0

Neurotechnology, a provider of high-precision biometric identification technologies, today announced the availability of VeriLook Surveillance 2.0, a software development kit (SDK) for biometric face identification using live video streams from single or multiple high-resolution digital surveillance cameras.

Dartmouth, Aeras to jointly conduct trial of DAR-901 vaccine against TB

Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

Amy Dover, LMFT - Couples Therapy in Enterprise, AL